NASDAQ:FLNA

Cassava Sciences Q2 2026 Earnings Results & Report

Cassava Sciences logo
$0.53 +0.05 (+11.15%)
As of 02:47 PM Eastern

Cassava Sciences reported Q2 2026 earnings on July 29, 2026. The company reported EPS of -$0.18.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

Cassava Sciences EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Q2 2026 Earnings FAQ

Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.18 per share for Q2 2026. The report was announced on Wednesday, July 29, 2026.

Cassava Sciences Earnings Headlines

Cassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option Buying
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:FLNA) is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences.

Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests.

Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.

View Cassava Sciences Profile